The 21st BioPharma Drug Discovery Nexus will be held on October 22-23, 2024, at the Holiday Inn Piscataway – Somerset, in New Jersey. New Jersey was selected as the venue for the event, as this northeastern state has been at the helm of biotech and pharma innovations and research. Experts from the region and all across the globe will grace the event and discuss challenges and opportunities in the field of drug discovery.
The event is organized by BioPharma Nexus, a trusted player in fostering connections between pharmaceutical and biotech companies, along with key service providers. Their goal is to provide the best healthcare to patients all over the globe. Service providers and businesses in biotech, pharma and…
To learn more, please visit https://ibn.fm/TKTOR.
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]
InvestorWire is powered by IBN